American Express, Biogen upgraded: Wall Street's top analyst calls
Wall Street analysts issued multiple rating changes. JPMorgan raised American Express (AXP) to Overweight, PT $400. Truist upgraded Biogen (BIIB) to Buy, PT $235, citing upcoming Phase 2 and Phase 3 readouts. JPMorgan also raised Keysight (KEYS) to Overweight, PT $400. Other actions included upgrades for Humana (HUM) and downgrades for Papa John’s (PZZA) and Best Buy (BBY).
How this was made
The 30-second read
Why it matters
The actionable element is the set of rating/target revisions tied to specific upcoming events (BIIB clinical data timing, SHOP implied Q2 beat) and valuation/cost-trend narratives (HUM Medicare Advantage costs, ABCB buybacks and mortgage recovery).
Market read
Traders can use the note to adjust near-term positioning around upcoming catalysts and to reassess valuation narratives embedded in the rating changes.
What to watch
For biotech, the key risk is data quality versus expectations (Phase 2 differentiation and Phase 3 readouts). For banks/insurers, the thesis hinges on cost trend and capital return assumptions that may not hold through the next reported period.
Background
This is a multi-name Wall Street note roundup featuring upgrades, downgrades, and several coverage initiations, each with a stated price target and a thesis.
Ticker impact
JPMorgan upgraded American Express to Overweight from Neutral and raised its price target to $400 from $328, citing defensive revenue quality.
Mildly positive bias for the next few sessions as traders price the upgrade; magnitude likely limited without new AXP-specific data.
The article provides a clear rating/target change and thesis, but no new earnings, guidance, or operational datapoint.
Truist upgraded Biogen to Buy from Hold with a higher $235 target, pointing to upcoming Phase 2 BIIB080 data and Phase 3 readouts.
Positive drift into next week’s Phase 2 BIIB080 presentation, with potential repricing around any data surprises.
The article links the rating change to concrete trial timing (AAIC next week, Q4 Phase 3) and expects differentiated Phase 2 results.
Jefferies upgraded Shopify to Buy from Hold and raised its target to $160 from $140, citing third-party data implying a fiscal Q2 beat.
Moderately positive near-term bias ahead of the fiscal Q2 results window referenced by the third-party data.
The catalyst is an implied beat from third-party data, not the actual results, and the article lacks additional Shopify-specific operational details.
Morgan Stanley upgraded Keysight Technologies to Overweight and lifted its target to $400 from $350, framing it as an AI investment and architecture-broadening play.
Slight positive bias, likely more sentiment-driven than fundamental until new KEYS-specific datapoints emerge.
Only an analyst rating/target change and thematic framing are provided, with no fresh company metrics.
Wells Fargo upgraded Humana to Overweight and raised its target to $502 from $227, saying moderating Medicare Advantage cost trends require a thesis refresh.
Potentially strong positive repricing if traders believe the cost trend narrative; otherwise, could fade if the next data contradicts.
The article includes a specific thesis refresh tied to Medicare Advantage cost trends, but provides no new Humana-specific financial datapoint.
BofA downgraded Papa John’s to Underperform and cut its target to $34 from $42, arguing it is unlikely the former CFO left without a sharp turnaround.
Negative near-term bias as traders reassess turnaround odds and valuation support.
The article provides a clear rating/target change and a specific rationale, though it is still an analyst inference rather than new company disclosure.
RBC Capital downgraded Kymera Therapeutics to Sector Perform and raised its target to $115 from $106, balancing oral dupi-like biomarker signals with risk/reward.
Choppy reaction possible: some support from biomarker de-risking expectations, offset by the more cautious overall stance.
The article references biomarker strength and potential M&A interest, but does not provide new trial results or dates beyond year-end Phase IIb AD de-risking.
Keefe Bruette downgraded Porch Group to Market Perform from Outperform and raised its target to $16.25 from $13, citing a 116% three-month rally as changing risk/reward.
Slightly negative to neutral near-term, as traders may take profits after the rally and reassess forward returns.
The article provides a concrete performance context (116% rally) and a rating change, but no new PRCH fundamentals.
Market effects
Cross-sector read-through: upgrades cluster in financials (AXP, HUM, ABCB), healthcare biotech (BIIB, KYMR, ALKS, SPRB), and tech/industrial instrumentation (SHOP, KEYS, HONA).
Primarily US-listed single-name sentiment; limited direct regional macro linkage in the text.
Biotech clinical timing (AAIC, Q4 readouts) can influence global biotech risk appetite, but the article is still analyst-driven rather than a new trial disclosure.
Counterpoint
Analyst rating and target changes may already be partially priced, especially where the catalysts are upcoming clinical presentations or implied earnings beats rather than newly reported results.
Key entities
- companyAmerican Express
JPMorgan upgraded to Overweight and raised its price target to $400 from $328.
- companyBiogen
Truist upgraded to Buy and raised its price target to $235 from $190 ahead of Phase 2/3 pipeline updates.
- companyShopify
Jefferies upgraded to Buy and raised its price target to $160 from $140 on expectations of a fiscal Q2 beat.
- companyHumana
Wells Fargo upgraded to Overweight and raised its price target to $502 from $227 on moderating Medicare Advantage cost trends.
- companyPapa John’s
BofA downgraded to Underperform and cut its price target to $34 from $42.
